Last reviewed · How we verify
NVP and AZT
NVP and AZT are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase to prevent viral replication.
NVP and AZT are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection, Prevention of mother-to-child transmission of HIV (PMTCT).
At a glance
| Generic name | NVP and AZT |
|---|---|
| Also known as | Nevirapine and zidovudine |
| Sponsor | Johns Hopkins Bloomberg School of Public Health |
| Drug class | Antiretroviral combination therapy (NNRTI + NRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV reverse transcriptase, while azidothymidine (AZT) is a nucleoside analog that is incorporated into the growing viral DNA chain, causing chain termination. Together, they represent a combination antiretroviral therapy approach targeting the same enzyme through different mechanisms to reduce viral load and delay resistance development.
Approved indications
- HIV-1 infection
- Prevention of mother-to-child transmission of HIV (PMTCT)
Common side effects
- Rash (NVP-associated)
- Hepatotoxicity
- Anemia (AZT-associated)
- Nausea
- Headache
- Neutropenia (AZT-associated)
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- A Study of Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Reduction of Mother-to-child HIV Transmission During Breastfeeding (PHASE2)
- A Prospective Cohort of Children With HIV Infection
- ARVs to Prevent Breastmilk HIV:Viral and Immune Responses (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NVP and AZT CI brief — competitive landscape report
- NVP and AZT updates RSS · CI watch RSS
- Johns Hopkins Bloomberg School of Public Health portfolio CI